Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASCO
Biotech
ASCO: Kura, Kyowa reveal 23% remission rate behind leukemia win
Kura and Kyowa Kirin have shared details of the phase 2 win for ziftomenib as the FDA mulls whether to greenlight the selective menin inhibitor.
James Waldron
Jun 2, 2025 5:36pm
Bicara CEO: ASCO data resonate more with 'people that matter'
Jun 2, 2025 4:26pm
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
ASCO: Chasing Merus, Bicara shares 2-year HNSCC survival data
Jun 1, 2025 3:36pm
ASCO: Kite's CAR-T flies high in phase 1 B-cell lymphoma study
May 31, 2025 7:00pm
ASCO: Immatics cell therapy sees 56% ORR in advanced melanoma
May 31, 2025 8:00am
